1 active not recruiting, 1 completed. 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow AZD9592: new trials by email Literature Review of AZD9592 trials Research Report on AZD9592
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC Rilvegostomig, Volrustomig, Sabestomig - Head and Neck Squamous Cell Carcinoma | Early Phase 1 | Completed | Presage Biosciences | 17 | 2024-05-22 | 2026-06-26 |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies Rilvegostomig, Volrustomig, Sabestomig - Solid Tumor | Early Phase 1 | Active not recruiting | Presage Biosciences | 15 | 2021-07-26 | 2026-05-22 |
Head and Neck Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Lymphoma (1) · Melanoma (1) · Sarcoma (1)
United States (2)